Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ARCT

Arcturus Therapeutics (ARCT)

Arcturus Therapeutics Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARCT
DateTimeSourceHeadlineSymbolCompany
03/06/20253:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/24/20253:01PMBusiness WireArcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025NASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/14/20257:30AMPR Newswire (US)European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/14/20257:00AMBusiness WireEuropean Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/04/20257:30AMBusiness WireArcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair DesignateNASDAQ:ARCTArcturus Therapeutics Holdings Inc
01/31/20252:00AMBusiness WireMeiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19NASDAQ:ARCTArcturus Therapeutics Holdings Inc
01/30/20253:01PMBusiness WireArcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
01/10/20257:00AMBusiness WireArcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine TrialNASDAQ:ARCTArcturus Therapeutics Holdings Inc
01/06/20253:01PMBusiness WireArcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:ARCTArcturus Therapeutics Holdings Inc
12/18/20243:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
12/16/20243:01PMBusiness WireArcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/26/20243:01PMBusiness WireArcturus Therapeutics to Attend Upcoming Investor ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/18/20247:00PMBusiness WireArcturus Therapeutics to Present at Jefferies London Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/14/202412:00AMBusiness WireMeiji Seika Pharma Announces Investment in ARCALIS, Inc.NASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/11/20243:01PMBusiness WireArcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical TrialNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/07/20243:25PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/07/20243:01PMBusiness WireArcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
10/31/20243:01PMBusiness WireArcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
09/30/20247:00AMPR Newswire (US)Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-VaccinationNASDAQ:ARCTArcturus Therapeutics Holdings Inc
09/30/20247:00AMBusiness WireSelf-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-VaccinationNASDAQ:ARCTArcturus Therapeutics Holdings Inc
09/13/20247:15AMPR Newswire (US)Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika PharmaNASDAQ:ARCTArcturus Therapeutics Holdings Inc
09/13/20247:00AMBusiness WireJapan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika PharmaNASDAQ:ARCTArcturus Therapeutics Holdings Inc
09/03/20247:30AMBusiness WireArcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/27/20244:00PMBusiness WireArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/13/20246:54AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/05/20243:50PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/05/20243:09PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/05/20243:01PMBusiness WireArcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
08/01/20243:01PMBusiness WireArcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
07/18/20246:30PMBusiness WireArcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:ARCT

Your Recent History

Delayed Upgrade Clock